InVivoMAb anti-mouse osteopontin (SPP1)

Bui TM, Yalom LK, Ning E, et al. Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer. J Clin Invest. 2024,134(7). doi: 10.1172/JCI174545

De Muynck K, Heyerick L, De Ponti FF, et al. Osteopontin characterizes bile duct-associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis. Hepatology. 2024,79(2):269-288. doi: 10.1097/HEP.0000000000000557

Bianchi E, Rontauroli S, Tavernari L, et al. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. Leukemia. 2023,37(5):1068-1079. doi: 10.1038/s41375-023-01867-3

Klement JD, Poschel DB, Lu C, et al. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel). 2021,13(5). doi: 10.3390/cancers13051006